Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518167-35-01

Acronym

AIEOP-ISG OsM+

Enrollment

Registered

2024-12-16

Start date

2025-12-19

Completion date

Unknown

Last updated

2025-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Metastatic Osteosarcoma

Brief summary

The primary end-point is 3-year Event Free Survival (EFS)

Interventions

DRUGMetotressato Teva 25 mg/ml soluzione iniettabile

DRUGDoxorubicina Teva 2 mg/ml concentrato per soluzione per infusione

DRUGXGEVA 120 mg solution for injection

DRUGCISPLATINO Pfizer 100 mg/100 ml soluzione per infusione

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The primary end-point is 3-year Event Free Survival (EFS)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026